Table 4.

Aggregate excess relative risks (per Sv) of circulatory disease by endpoint (reproduced from Ref. [101]).

Endpoint	Studies included	ERR Sv−1 (95% CI)	Heterogeneity
Heart	Darby et al. [149] a, Preston et al. [8] b, Talbott et al. [147] b, Yamada et al. [9] c, Carr et al. [150] d, Ivanov et al. [12] e, Kreuzer et al. [148] b, Vrijheid et al. [16] a, Azizova and Muirhead [15] f	0.07 (0.04, 0.11)	p = 0.00085
Stroke	Darby et al. [149] g, Preston et al. [8] g, Yamada et al. [9] h, Ivanov et al. [12] h, Kreuzer et al. [148] g, Vrijheid et al. [16] g, Azizova and Muirhead [15] h, Muirhead et al. [14] g	0.27 (0.20, 0.34)	p = 0.00004
Morbidity	Yamada et al. [9] c,h,i, Ivanov et al. [12] j, Azizova and Muirhead [15] f,h	0.10 (0.07, 0.13)	p < 10−10
Mortality	Darby et al. [149] a,g, Davis et al. [65] k, Preston et al. [8] b,g, Talbott et al. [147] b, Carr et al. [150] d, Kreuzer et al. [148] k, Vrijheid et al. [16] k, Muirhead et al. [14] k	0.03 (−0.02, 0.08)	p = 0.00003
Total	Darby et al. [149] a,g, Davis et al. [65] k, Preston et al. [8] b,g, Talbott et al. [147] b, Yamada et al. [9] c,h,i, Carr et al. [150] d, Ivanov et al. [12] j, Kreuzer et al. [148] k, Vrijheid et al. [16] k, Azizova and Muirhead [15] f,h, Muirhead et al. [14] k	0.08 (0.05, 0.11)	p < 10−13

^aAnalysis based on all circulatory disease mortality apart from stroke.

^bAnalysis based on all heart disease mortality.

^cAnalysis based on morbidity from hypertensive heart disease, ischaemic heart disease.

^dAnalysis based on coronary heart disease and other heart disease mortality, excluding highest dose group (3.1–7.6 Gy).

^eAnalysis based on mortality from hypertension, ischaemic heart disease and other heart disease.

^fAnalysis based on morbidity from ischaemic heart disease.

^gAnalysis based on stroke mortality.

^hAnalysis based on stroke morbidity.

ⁱAnalysis based on hypertension morbidity.

^jAnalysis based on all circulatory disease morbidity.

^kAnalysis based on all circulatory disease mortality.